The third major contender for a COVID-19 vaccine, Johnson & Johnson , published its Phase 3 interim analysis data on Friday. The vaccine's name is EMSEMBLE. ENSEMBLE, distinguishable for its existence as a single-dose vaccine, showed effectiveness in 72% of recipients who participated in the Phase 3 trials, numbering at 43,783. "Our goal all along has been to create a simple, effective solution for the largest number of people possible ...